Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Ascl1 protein. Show all posts
Showing posts with label Ascl1 protein. Show all posts

Monday, February 10, 2025

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

 Is this far enough along for your competent? doctor TO ENSURE HUMAN TESTING GETS DONE? You mean your doctor has no idea on contacting leadership to get necessary research accomplished? And s/he HASN'T BEEN FIRED YET?

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

Ischemic stroke, the second leading cause of death worldwide and the leading cause of long-term disabilities, presents a significant global health challenge, particularly in aging populations where the risk and severity of cerebrovascular events are significantly increased. The aftermath of stroke involves neuronal loss in the infarct core and reactive astrocyte proliferation, disrupting the neurovascular unit, especially in aged brains. Restoring the balance between neurons and non-neuronal cells within the perilesional area is crucial for post-stroke recovery. The aged post-stroke brain mounts a fulminant proliferative astroglial response, leading to gliotic scarring that prevents neural regeneration. While countless therapeutic techniques have been attempted for decades with limited success, alternative strategies aim to transform inhibitory gliotic tissue into an environment conducive to neuronal regeneration and axonal growth through genetic conversion of astrocytes into neurons. This concept gained momentum following discoveries that in vivo direct lineage reprogramming in the adult mammalian brain is a feasible strategy for reprogramming non-neuronal cells into neurons, circumventing the need for cell transplantation. Recent advancements in glial cell reprogramming, including transcription factor-based methods with factors like NeuroD1, Ascl1, and Neurogenin2, as well as small molecule-induced reprogramming and chemical induction, show promise in converting glial cells into functional neurons. These approaches leverage the brain’s intrinsic plasticity for neuronal replacement and circuit restoration. However, applying these genetic conversion therapies in the aged, post-stroke brain faces significant challenges, such as the hostile inflammatory environment and compromised regenerative capacity. There is a critical need for safe and efficient delivery methods, including viral and non-viral vectors, to ensure targeted and sustained expression of reprogramming factors. Moreover, addressing the translational gap between preclinical successes and clinical applications is essential, emphasizing the necessity for robust stroke models that replicate human pathophysiology. Ethical considerations and biosafety concerns are critically evaluated, particularly regarding the long-term effects and potential risks of genetic reprogramming. By integrating recent research findings, this comprehensive review provides an in-depth understanding of the current landscape and future prospects of genetic conversion therapy for ischemic stroke rehabilitation, highlighting the potential to enhance personalized stroke management and regenerative strategies through innovative approaches.

Monday, November 11, 2024

Reprogrammed Brain Cells Could Restore Damaged Circuits

 Do you really think your competent? doctor and hospital will get followup research done on this to repair stroke damaged brains?

Reprogrammed Brain Cells Could Restore Damaged Circuits

Summary: Scientists have successfully reprogrammed astroglia, a type of brain support cell, into neurons that mimic specific interneurons critical for brain function. By modifying the Ascl1 protein, they increased its efficiency in converting astroglia to neuron-like cells, opening new possibilities for regenerative treatments for brain disorders such as epilepsy.

The engineered neurons exhibit high-frequency firing, a signature of certain interneurons essential for regulating brain activity. This work suggests astroglia could serve as a repair mechanism, allowing us to restore lost or damaged brain circuits.

Key Facts:

  • Modified Ascl1 protein effectively converts astroglia into functional neurons.
  • Reprogrammed neurons exhibit high-frequency firing, crucial for brain circuit control.
  • This approach holds potential for treating conditions like epilepsy by restoring neural circuits.

Source: King’s College London

Researchers have successfully demonstrated how astroglia – cells that support the functioning of the brain – can be reprogrammed into cells resembling interneurons.

The research, published in Science Advances, represents not only an important step forward in neuronal engineering, but also has vital implications for regenerative medicine, which researchers hope could be used to restore dysfunctional brain circuits like those seen in people with epilepsy.

This shows neurons.
They found that when mutated, Ascl1 became highly efficient in converting astroglia into functioning neurons, much more so than the form of the protein that is generated naturally by the body. Credit: Neuroscience News

Working with mice shortly after birth, researchers coaxed astroglia to synthesize a protein, Ascl1, that plays a key role in the development of the nervous system.

They found that when mutated, Ascl1 became highly efficient in converting astroglia into functioning neurons, much more so than the form of the protein that is generated naturally by the body.

“While the neurons we induced differ from those the body creates itself, we’re excited to show that engineered neurons can acquire highly specific properties.

“Our findings will allow us to further close the gap between induced and endogenous neurons and thereby render them ever more useful for future translation in regenerative medicine.” Said Professor Benedikt Berninger, Professor of Developmental Neurobiology at King’s IoPPN and the study’s senior author

The research team found that the neurons they generated displayed properties that were similar to those native to the brains they were working on, including the ability to fire at very high frequencies, a telltale hallmark of a particular class of interneurons that play a vital role in regulating brain circuitry.

Dr Nicolás Marichal, Research Associate at the Centre for Developmental Neurobiology at King’s IoPPN and one of the study’s lead authors said, “This landmark study’s success in creating neurons from astroglia breaks new ground in regenerative medicine, offering promise for the restoration of aberrant circuitry and brain function in neurological conditions.

“This work paves the way for further research to exploit these findings and leverage lineage reprogramming of glia into subtype specific neurons as a new therapeutic avenue.”

Funding: This research was funded in part by Wellcome Trust, the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme, and the German Research Foundation.

About this neuroscience research news

Author: Benedikt Berninger
Source: King’s College London
Contact: Benedikt Berninger – King’s College London
Image: The image is credited to Neuroscience News

Original Research: Open access.
Reprogramming astroglia into neurons with hallmarks of fast-spiking parvalbumin-positive interneurons by phospho-site–deficient Ascl1” by Benedikt Berninger et al. Science Advances